Awareness of Medication-Related Osteonecrosis of the Jaws Amongst Patients on Antiresorptive and Antiangiogenic Medications
- PMID: 38406100
- PMCID: PMC10891455
- DOI: 10.7759/cureus.52896
Awareness of Medication-Related Osteonecrosis of the Jaws Amongst Patients on Antiresorptive and Antiangiogenic Medications
Abstract
Background Medication-related osteonecrosis of the jaws (MRONJ) is a rare but severe condition that has garnered increasing attention in recent years. It primarily affects individuals undergoing treatment with antiresorptive and antiangiogenic medications, such as bisphosphonates and denosumab, commonly prescribed for osteoporosis and cancer-related bone metastases. Therefore, the present study aimed to assess awareness and understanding of MRONJ among patients receiving antiresorptive and antiangiogenic medications. Methods A cross-sectional survey was conducted among 110 patients receiving antiresorptive and antiangiogenic medications in a clinical setting. Participants were given a structured questionnaire to assess their awareness of MRONJ. The questionnaire covered aspects such as MRONJ, bisphosphonate usage, and awareness of the condition's potential complications. Demographic information was also collected. Chi-square and Fisher's tests were performed using SPSS statistical software. Results In terms of gender distribution, 63.6% of the participants were female. Concerning age distribution, the majority (43.6%) fell within the 21 to 40 age group, whereas only 5.5% were aged over 60. Regarding educational attainment, a substantial majority (58.2%) of the participants held a bachelor's degree. The study findings reveal that a considerable proportion (35.5%) of participants possess awareness regarding jaw osteonecrosis, and this association is statistically significant (p=0.002). A substantial number of participants administered the medication orally (30.9%), while others utilized various administration routes, including injection (IV and others) (40%), and this difference was also statistically significant (p=0.001). Most participants took bisphosphonates for osteoporosis (41.8%) or cancer (13.6%), both statistically significant (p<0.01). Gender had no significant impact (p>0.01), but age showed potential associations (p=0.07 for awareness, p=0.003 for medication use). Educational backgrounds had no significant link, except for bisphosphonate usage (p<0.01) and side effects reporting (p<0.01). Conclusion Notably, a small percentage of participants demonstrated awareness of this condition, indicating a need for continued education and awareness campaigns. Further research and interventions may be warranted to address the specific needs of different age groups and educational backgrounds in promoting safe and effective medication management.
Keywords: bisphosphonates; dental care for medicatpatient educationion users; jaws osteonecrosis; medication-related osteonecrosis; mronj; oral health risks; patient awareness; patient education.
Copyright © 2024, Assari et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.Minerva Stomatol. 2017 Aug;66(4):135-140. doi: 10.23736/S0026-4970.17.04056-0. Epub 2017 May 10. Minerva Stomatol. 2017. PMID: 28497661
-
Emerging antiresorptive medications and their potential implications for dental surgeries.J Am Dent Assoc. 2022 Jul;153(7):649-658. doi: 10.1016/j.adaj.2021.12.008. Epub 2022 Mar 8. J Am Dent Assoc. 2022. PMID: 35277242 Review.
-
The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):509-16. doi: 10.1016/j.coms.2015.06.003. Epub 2015 Sep 9. Oral Maxillofac Surg Clin North Am. 2015. PMID: 26362367 Review.
-
Dental practitioners' and students' knowledge of medication related osteonecrosis of the jaw (MRONJ).Saudi Pharm J. 2021 Jan;29(1):96-103. doi: 10.1016/j.jsps.2020.12.012. Epub 2020 Dec 29. Saudi Pharm J. 2021. PMID: 33603544 Free PMC article.
-
Awareness among patient at risk of developing Medication Related Osteonecrosis of the Jaw (MRONJ) - A primary prevention strategy.Saudi Pharm J. 2020 Jun;28(6):771-778. doi: 10.1016/j.jsps.2020.05.004. Epub 2020 May 15. Saudi Pharm J. 2020. PMID: 32550810 Free PMC article.
Cited by
-
How does medication-related osteonecrosis of the jaw (MRONJ) influence the health-related quality of life after surgery?BMC Oral Health. 2025 Jun 21;25(1):951. doi: 10.1186/s12903-025-06171-3. BMC Oral Health. 2025. PMID: 40544272 Free PMC article.
References
-
- Clinician's guide to prevention and treatment of osteoporosis. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R. https://link.springer.com/article/10.1007/s00198-014-2794-2. Osteoporos Int. 2014;25:2359–2381. - PMC - PubMed
-
- Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis Diagnosis, and Therapy. JAMA. 2001;285:785–795. - PubMed
-
- The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, Mohammadi M. https://link.springer.com/article/10.1186/s13018-021-02772-0. J Orthop Surg Res. 2021;16:609. - PMC - PubMed
-
- Osteoporosis. Lane JM, Russell L, Khan SN. https://journals.lww.com/clinorthop/fulltext/2000/03000/osteoporosis.16.... Clin Orthop Relat Res. 2000;10372:139. - PubMed
-
- Awareness among patient at risk of developing Medication Related Osteonecrosis of the Jaw (MRONJ) - A primary prevention strategy. Al Abdullateef A, Alhareky MS. https://www.sciencedirect.com/science/article/pii/S1319016420301079 Saudi Pharmaceutical J. 2020;10:771–778. - PMC - PubMed
LinkOut - more resources
Full Text Sources